Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIG1 domain family member 2B (HIGD2B) is annotated as a member of the HIGD family based on sequence similarity, but there is limited to no published experimental evidence supporting its protein-coding status or biological function. It may correspond to a pseudogene or represent a gene prediction artifact, as reflected by its alias "putative HIG1 domain family member 2B" and "HIG1 hypoxia inducible domain family, member 2B (pseudogene)". No evidence currently supports its role as a therapeutic target, as a receptor, enzyme, or transporter, or its involvement in any established signaling pathways or diseases. In contrast, family members such as HIGD1A have clearly described roles in mitochondrial biology and stress response, but this cannot be inferred to HIGD2B without direct evidence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIG1 domain family member 2B (HIGD2B).